{"id":"W2762460629","doi":"10.1093/annonc/mdx374","title":"Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"MacroGenics; Genentech; AstraZeneca; Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Head and neck squamous-cell carcinoma; Internal medicine; Clinical endpoint; Oncology; Immunotherapy; Regimen; Chemotherapy; Phases of clinical research; Radiation therapy; Cancer; Head and neck cancer; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001385029,0.001147395,0.002053958,0.0002381479,0.0003356767,0.0008095877,0.0006355152,0.0006770351,0.001598094],"category_scores_gemma":[0.000619538,0.0003454496,0.001155708,0.0002700409,0.0006034859,0.0007657562,0.0002178115,0.001871208,0.0005338233],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001040133,"about_ca_system_score_gemma":0.001108458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002334793,"about_ca_topic_score_gemma":0.01140543,"domain_scores_codex":[0.9996932,0.0001143254,0.00001433588,0.00004743927,0.00003889852,0.00009195122],"domain_scores_gemma":[0.9996843,0.00007065624,0.00004877459,0.00003567211,0.00002479085,0.0001357738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5096552,0.03640129,0.01540954,0.001665693,0.003652706,0.0006919748,0.0005951921,0.003158266,0.07424572,0.0003054387,0.005597966,0.348621],"study_design_scores_gemma":[0.5033419,0.4240078,0.04737272,0.0001058114,0.002667543,0.001134997,0.00029478,0.003170705,0.01142405,0.0004338186,0.005972694,0.00007315078],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948205,0.002544534,0.0002712684,0.000208389,0.00006844358,0.0004686803,0.0005235192,0.00005798802,0.001036692],"genre_scores_gemma":[0.9913301,0.003061689,0.00112195,0.0005233728,0.00008810153,0.0004753077,0.001383565,0.00003722965,0.00197845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002334793,"threshold_uncertainty_score":0.007546723,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1613044525875613,"score_gpt":0.4264112029151277,"score_spread":0.2651067503275664,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}